Doctor of Philosophy (Ph.D.)

Pharmaceutics and Industrial Pharmacy
University of Ibadan
2011

Master of Business Administration (M.B.A.)

Pharmacy/Management
Obafemi Awolowo University
1999

Master of Science (M.S.)

Pharmaceutics
Obafemi Awolowo University
1995

Bachelor of Pharmacy (B.Pharm.)

Pharmacy (B.Pharm.)
Obafemi Awolowo University
1989

Master of Science (M.S.)

Health Informatics
University of Illinois
2020

Drug Delivery & Targeting

• Drug targeting with peptides to bacterial & cancer cells
• PK Modeling and Simulations
• Statistical Design of Experiments, Healthcare Data Intelligence/Analysis & Visualization

Pharmaceutical Unit Operations

• Pre-formulation Studies
• Dosage form design and evaluation
• Instrumental methods of analysis, stability & shelf-life extension studies

Pharmaceutical microbiology

• Culture & sensitivity studies
• Antibiotic assays
• Antibacterial efficacy studies

NAPLEX/MPJE Preparatory Course

Pharmaceutics

Pharmaceutical Calculations

Biopharmaceutics & Pharmacokinetics

Pharmaceutical Unit Operations (PhD)

Biopharmaceutics & Pharmacokinetics Modeling & Simulations (PG Elective)

Pharmaceutical Compounding

Faculty of the Year Award, 2025-26

Excellence in Teaching Award, Office of the Dean, College of Pharmacy 2025.

Biggest Heart Award, Roosevelt University College of Pharmacy, Schaumburg, IL2014

President's Research Initiative Award, University of Technology, Jamaica, 2005.

Development and Characterization of Optimized Drug-Loaded Niosomes for Delivery of 5-FU and Irinotecan

Development and Characterization of Optimized Drug-Loaded Niosomes for Delivery of 5-FU and Irinotecan

5-Fluorouracil (5-FU) and Irinotecan (IRT) are two of the most used chemotherapeutic agents in CRC treatment. However, achieving treatment goals has been hampered by poor drug delivery to tumor sites and associated toxicity from off-target binding to healthy cells. Though the synergism of 5-FU-IRT has provided incremental improvements in clinical outcomes, the short elimination half-life and off-target binding to healthy cells remain significant challenges. We postulated that nanoencapsulation of a combination of 5-FU and IRT in niosomes would prolong the drugs’ half-lives, while over-encapsulation lyophilized powder in Targit® oral capsules would passively the CRC microenvironment and avoid extensive systemic distribution.

Colorectal Cancer

Colorectal Cancer: Therapeutic Approaches and Their Complications

This paper discusses the standard therapeutic approaches to managing colorectal cancer, the associated complications, and their management. In addition, a summary of the newly introduced therapeutic approaches for treating CRC, reported improvement in effectiveness over existing strategies and corresponding reduction in therapeutic complications will be discussed.

Pharmacokinetics of Levofloxacin Entrapped in Non-Ionic Surfactant Vesicles (Niosomes) in Sprague Dawley Rats

Pharmacokinetics of Levofloxacin Entrapped in Non-Ionic Surfactant Vesicles (Niosomes) in Sprague Dawley Rats

Bacteria are becoming increasingly resistant to levofloxacin and other fluoroquinolones. Previously, drug loading in colloidal carriers has shown enhanced penetration into and retention in bacterial cells. However, the mechanism of levofloxacin niosomes’ bio-disposition in rats has not been reported. This study investigated the pharmacokinetics (PK) of optimized levofloxacin niosomes following intraperitoneal injection into Sprague Dawley rats.

PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer

PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer

Active targeting to cancer involves exploiting specific interactions between receptors on the surface of cancer cells and targeting moieties conjugated to the surface of vectors such that site-specific delivery is achieved. Prostate specific membrane antigen (PSMA) has proved to be an excellent target for active targeting to prostate cancer. We report the synthesis and use of a PSMA-specific ligand (Glu-NH-CO-NH-Lys) for the site-specific delivery of brusatol- and docetaxel-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles to prostate cancer. The PSMA targeting ligand covalently linked to PLGA-PEG 3400 was blended with methoxyPEG-PLGA to prepare brusatol- and docetaxel-loaded nanoparticles with different surface densities of the targeting ligand. Flow cytometry was used to evaluate the impact of different surface densities of the PSMA targeting ligand in LNCaP prostate cancer cells at 15 min and 2 h. Cytotoxicity evaluations of the targeted nanoparticles reveal differences based on PSMA expression in PC-3 and LNCaP cells. In addition, levels of reactive oxygen species (ROS) were measured using the fluorescent indicator, H 2 DCFDA, by flow cytometry. PSMA-targeted nanoparticles loaded with docetaxel and brusatol showed increased ROS generation in LNCaP cells compared to PC-3 at different time points. Furthermore, the targeted nanoparticles were evaluated in male athymic BALB/c mice implanted with PSMA-producing LNCaP cell tumors. Evaluation of the percent relative tumor volume show that brusatol-containing nanoparticles show great promise in inhibiting tumor growth. Our data also suggest that the dual drug-loaded targeted nanoparticle platform improves the efficacy of docetaxel in male athymic BALB/c mice implanted with PSMA-producing LNCaP cell tumors.

Colorectal Cancer

Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives

Colorectal cancer (CRC) is one of the deadliest malignancies in the US, ranking fourth after lung, prostate, and breast cancers, respectively, in general populations. It continues to be a menace, and the incidence has been projected to more than double by 2035, especially in underdeveloped countries. This review seeks to provide some insights into the disease progression, currently available treatment options and their challenges, and future perspectives. Searches were conducted in the PubMed search engine in the university’s online library. The keywords were “Colorectal Cancer” AND “disease process” OR “disease mechanisms” OR “Current Treatment” OR “Prospects”. Selection criteria were original articles published primarily during the period of 2013 through 2023. Abstracts, books and documents, and reviews/systematic reviews were filtered out. Of over 490 thousand articles returned, only about 800 met preliminary selection criteria, 200 were reviewed in detail, but 191 met final selection criteria. Fifty-one other articles were used due to cross-referencing. Although recently considered a disease of lifestyle, CRC incidence appears to be rising in countries with low, low–medium, and medium social demographic indices. CRC can affect all parts of the colon and rectum but is more fatal with poor disease outcomes when it is right-sided. The disease progression usually takes between 7–10 years and can be asymptomatic, making early detection and diagnosis difficult. The CRC tumor microenvironment is made up of different types of cells interacting with each other to promote the growth and proliferation of the tumor cells. Significant advancement has been made in the treatment of colorectal cancer. Notable approaches include surgery, chemotherapy, radiation therapy, and cryotherapy. Chemotherapy, including 5-fluorouracil, irinotecan, oxaliplatin, and leucovorin, plays a significant role in the management of CRC that has been diagnosed at advanced stages. Two classes of monoclonal antibody therapies have been approved by the FDA for the treatment of colorectal cancer: the vascular endothelial growth factor (VEGF) inhibitor, e.g., bevacizumab (Avastin®), and the epidermal growth factor receptor (EGFR) inhibitor, e.g., cetuximab (Erbitux®) and panitumumab (Verbitix®). However, many significant problems are still being experienced with these treatments, mainly off-target effects, toxic side effects, and the associated therapeutic failures of small molecular drugs and the rapid loss of efficacy of mAb therapies. Other novel delivery strategies continue to be investigated, including ligand-based targeting of CRC cells.